HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that they have entered into an exclusive distribution agreement. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration Matrices for use in patients in India.
M. V. Ramana, Executive Vice President and Head of Emerging Markets & India Business, Dr. Reddy’s Laboratories said, “We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery.”
“Our market-leading DuraGen products have helped more than one million patients worldwide,” said Glenn Coleman, Chief Financial Officer and Corporate Vice President, International, Integra LifeSciences. “This collaboration will allow us to continue to expand patient access globally and provide innovative regenerative technology solutions to neurosurgeons and patients in India.”
The DuraGen product line offers Duraplasty Solutions™ meant for the repair of the dura mater. Dura mater is a thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid (CSF). DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater. It offers a simple technique for precise placement of the matrix as an onlay graft in cranial and spinal procedures, and easily conforms to the complex surfaces of exposed neural tissue. It provides effective protection against CSF leakage with sutureless closure and is fully resorbed and replaced by native tissue with complete dural closure.
Suturable DuraGen matrix is a versatile graft that can be sutured and is designed for repairing dural defects where mechanical anchoring of the graft is preferred. This offers excellent suture retention with all the benefits of DuraGen Plus Matrix.
Integra's DuraGen products have been implanted in more than 1.8 million patients worldwide to effect dural closure following neurosurgical procedures. Integra manufactures the DuraGen family of products based on its proprietary Ultra Pure Collagen™ technology platform.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.
About Integra LifeSciences Corporation: Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.
The company assumes no obligation to update any information contained herein.
Studies conducted to date clearly indicate that IQOS is likely to present less risk of harm compared to smoking
LAUSANNE, Switzerland--(BUSINESS WIRE)--Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today announces the positive results from an advanced clinical study on IQOS, the company’s first electronically heated tobacco product, published in the peer-reviewed journal Nicotine & Tobacco Research.
Conducted in Japan over a three-month period by the well-known clinical research organization, the Osaki Hospital Tokyo Heart Center, the study showed that smokers who switched to IQOS:
- Reduced their exposure to 15 harmful chemicals to levels that approached those of smokers who quit smoking;
- Showed improvements in measured health indicators specific to smoking-related diseases, such as lung and heart disease. In all cases, the health indicators improved in the same direction as seen in smokers who quit. Further testing through a longer-term study is underway; and
- Found the product satisfying and were likely to completely switch to it.
The research was conducted in line with internationally respected guidelines for clinical trials, such as Good Clinical Practice as defined by the International Conference for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. 160 smokers were divided into three groups: continued smoking, quitting, and complete switching to IQOS. Participants spent five days at a clinic and continued the experiment at home for an additional 85 days, during which time biological samples and measurements were regularly taken.
PMI’s research program to confirm the risk reduction potential of IQOS includes laboratory and clinical studies, research on actual product use, and evaluation of how well smokers understand communications related to reduced risk. This and a related study are the latest of an eight-part clinical research program completed on IQOS to support reduced exposure and preliminary improvements in health outcomes. A one-year study with about 1,000 participants is currently ongoing to further support the current strong indications of risk reduction.
PMI’s Chief Medical Officer, Dr. Frank Lüdicke, said: “This study is an important step to confirm that while IQOS is not risk-free, it is a better choice for the millions of smokers who do not quit. It clearly indicates that smokers who switch to IQOS reduce their exposure to harmful compounds to levels that approach those of smokers who quit smoking. The study also clearly indicates areas of significant risk reduction which we are currently confirming through a longer term study.”
PMI is committed to replacing cigarettes with smoke-free products as soon as possible to the benefit of smokers, society and public health. Over 1.4 million smokers have already switched to IQOS, and the company has plans to expand commercialization to key cities in 30-35 countries by the end of 2017. Since 2008, PMI has hired over 400 scientists and experts and invested over USD 3 billion in research, development and early commercialization for its portfolio of smoke-free products. The company has published over 200 peer-reviewed publications and book chapters in the past ten years.
The study is available on www.pmiscience.com.
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of Reduced-Risk Products (RRPs). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.
Philip Morris International media office
T: +41 (0)58 242 4500
Will become Okura Nikko Hotels’ fourth hotel in Vietnam
TOKYO--(BUSINESS WIRE)--Okura Nikko Hotel Management Co., Ltd., a subsidiary of Hotel Okura Co., Ltd., announced today that it has agreed with Chuo Vietnam Co., Ltd., a subsidiary of Chuo Limited Liability Company, owned by Daiwa House Industry Co., Ltd., and Fujita Corporation to manage Hotel Nikko Hai Phong when it opens for business in Hai Phong, Vietnam in 2020. The 269-room hotel will be operated under the Nikko Hotels International (NHI).
Hai Phong, which is some 100 kilometers east of Hanoi, the capital of Vietnam, is one of Vietnam’s most developed coastal cities. Hotel Nikko Hai Phong will be located within Waterfront City, a coastal district under development. The average hotel room will be 35 square meters large and guests will have choices of traditional Japanese dining and all-day dining and bar facilities.
Okura Nikko Hotel Management CEO Marcel P. van Aelst said, “Hai Phong offers robust transportation infrastructure, including motorways and an international airport. The city is attracting numerous Japanese multinational corporations, which is expected to create strong demand for accommodations in the Hai Phong area. NHI looks forward to offering sophisticated hospitality services and exceptionally comfortable hotel experiences for visitors to Hai Phong”
Hotel Nikko Hai Phong will be Okura Nikko Hotel Management’s fourth hotel to open in Vietnam, after Hotel Nikko Hanoi (1998), Hotel Nikko Saigon (2011) and the to-be-opened The Okura Prestige Saigon (2020). Aiming to operate 100 hotels worldwide by 2020, Okura Nikko Hotel Management is focusing on developing properties in the fast-growing Asian region. Investment in Vietnam is closely aligned with the strategy to optimize hotel management efficiency and increase brand recognition by venturing into countries with strong economic growth.
About Okura Nikko Hotel Management
Hotel Okura Co., Ltd. was founded in 1958 and opened its flagship Hotel Okura Tokyo in 1962. Hotel Okura has extensive expertise in the hospitality world, including asset ownership and hotel development, as well as hotel management, restaurant business and chain operations through its subsidiaries and other group companies. The brand unites its member hotels under the Best Accommodation, Cuisine and Service (Best A.C.S.) philosophy to ensure that all guests enjoy Okura’s signature hospitality, which combines Japanese attention to detail and Western functionality. Please visit www.okura.com.
Okura Nikko Hotel Management Co., Ltd., a subsidiary of Hotel Okura operates 74 properties (49 in Japan and 25 overseas) encompassing nearly 23,000 guest rooms (March 1, 2017) under three hotel groups: Okura Hotels & Resorts, Nikko Hotels International and Hotel JAL City. Please visit www.okura-nikko.com.
About Daiwa House Industry Co., Ltd.
Daiwa House Industry is a major Japanese housing and construction company founded in 1955. The company offers diverse products spanning a wide field, centering on single-family houses and also including condominiums, commercial facilities and general business-use buildings.
About Fujita Corporation
Fujita Corporation, a construction company within the Daiwa House Group, has managed numerous urban development projects and important facilities in Japan. The company celebrated its 100th anniversary in 2010.
Okura Nikko Hotel Management Co., Ltd.
Ms. Shoko Amano / Ms. Ikuko Arai / Mr. Ryutaro Suzuki, +81-3-6864-2734
４月に府南部で開幕する「お茶の京都博」に向けて、京都府山城広域振興局は山城地域１２市町村ごとのトレーディングカード「京都やましろココきてカード」を作成した。府南部がエリアの日本遺産「日本茶８００年の歴史散歩」の情報や写真などを掲載している。 表面は、日本遺産 ...
【行列覚悟】寿司も浜焼きもぜーんぶ半額！ 「大庄水産 水道橋店」最強コスパのオープニング
漁師料理専門店「大庄水産」の都内最大店舗が、2017年3月29日、東京都千代田区「JR水道橋駅（東口）徒歩2分」にオープンします。 オープン記念キャンペーンでは、29日と30日の2日間限定で、名物メニューすべてが"半額"になります。対象は「鮮魚刺盛」全種、「浜焼きセット」 ...
１月２５日に発生した学校給食による集団食中毒で、御坊市は２７日、管理監督の立場にあった奥幹夫教育長ら４人を厳重注意処分にしたと発表した。教育長のほか教育次長、教育総務課長、給食センター長で、「関係者に苦痛を与え、不安を抱かせた責任は重い」とした。 Tweet ...